Recto-Bartholin's duct fistula: a case report.

Bartholin's duct cysts, the most common growths in the vulva, occur in the labia majora. The cyst may become infected, and an abscess may develop in the gland. Rectovaginal fistula is a rare complication and its formation is secondary to Bartholin's cyst; only 4 cases have been reported in the literature so far. In this case, the fistula was located between the rectum and a Bartholin's duct, rather than the vagina and the rectum. We present the first case of a recto-Bartholin's duct fistula, performed surgical excision and fistulectomy. Postoperative treatment with antibiotics resulted in the complete resolution of all lesions at the 3-month follow-up.

Interdigitating dendritic cell sarcoma occured alone in axilla.

Interdigitating dendritic cell sarcoma (IDCS) is a very rare disease around the world and its prognosis is known to be aggressive. This reports a case diagnosed as IDCS of the axillary region treated in Soonchunhyang University Hospital. A 57-year-old female visited Soonchunhyang University Hospital with a left axillary mass. The mass was hard and fixed. Computed tomography observed a 7 cm lymph node at the left axilla, and core biopsy suspected sarcoma. In another study, there was no specific finding except the axillary lesion. Left axillary lymph node dissection (level I, II) was conducted and the pathologic report finally showed IDCS. The patient was treated with only radiotherapy and followed up without recurrence for 13 months up to now. IDCS is a very rare sarcoma that is hard to diagnose and progresses fast. Thus, treatment is very difficult. Proper treatment can be better established after more experiences.

Clinicopathologic change of gastrointestinal stromal tumor after neoadjuvant imatinib followed by surgical resection.

A 53-year-old woman was diagnosed with gastrointestinal stromal tumor (GIST) of the stomach. Computed tomography (CT) revealed a huge mass (12 cm in diameter), likely to invade pancreas and spleen. In the operation field, the tumor was in an unresectable state. The patient was then started on imatinib therapy for 4 months. On follow-up imaging studies, the tumor almost disappeared. We performed total gastrectomy and splenectomy upon which two small-sized residual tumors were found on microscopy. In this paper, we describe a case of clinicopathologic change in unresectable GIST after neoadjuvant imatinib mesylate.